Assessing Extended Treatment Interval on the Prognosis of Multiple Myeloma

In patients with multiple myeloma (MM), extended treatment interval is unfavorable for some but may have a small impact on certain subgroups, according to a study published in Oncology Research and Treatment.

Researchers retrospectively analyzed 122 patients with MM from January 2007 to June 2018, looking at data such as age, International Staging System , and chromosome. They analyzed treatment intervals and used the Cox proportional hazard regression model to analyze overall survival (OS) and progression-free survival. The researchers utilized the Kaplan-Meier method in survival analysis, and the log-rank test was used for assessing survival.

According to the results of the study, prolonging the interval treatments (>28 days) diminished OS in younger and high-risk subgroups, whereas OS was unaffected in older and low-risk subgroups. The researchers observed that OS was also reduced in transplant-eligible patients who did not receive a transplant. The results of univariate and multivariate analyses showed that extension of treatment interval was a risk factor for shortening OS. It was noted that prolonged treatment interval was due to iatrogenic and family reasons.

The researchers concluded, “Extended treatment interval is unfavorable in young and high-risk [patients with] MM and those suitable for transplantation but who did not receive a transplant. However, it has a faint impact on the elderly and low-risk subgroups.”